UNSPSC 51381905: Parecoxib

This classification denotes a cyclooxygenase inhibitor with the molecular formula C19H18N2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9TUW81Y3CE, chemically known as propanamide, n-((4-(5-methyl-3-phenyl-4-isoxazolyl)phenyl)sulfonyl)- but generally known as parecoxib, which bears US NIH Compound Identifier 119828. European Medicines Agency schedules Parecoxib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03650MIG.

UNSPSC 51381905 Parecoxib is a Commodity code nominally covering a specific nonsteroidal anti-inflammatory drug; however, the recent state and local procurement activity tagged to this code does not reflect pharmaceutical purchasing under that specification. The single recent opportunity shows a fundamental mismatch between the code's nominal scope and actual buying activity. Seminole County, Florida released an IFB (Invitation for Bid) in June 2026 seeking naloxone and safe drug deactivation systems—products unrelated to parecoxib procurement. This divergence suggests either a data classification error or a broader use of the code as a catch-all for emergency medical supply or pharmaceutical-adjacent commodities in state and local systems.

The geographic reach and issuing-body pattern cannot be reliably characterized from a single misaligned opportunity. Seminole County's naloxone and deactivation-systems bid (IFB 60459723LAS, due July 26, 2023) represents the only recent activity visible under this code; it called for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, on a two-year initial term with one-year renewal option. The procurement required electronic submission through the county's e-Procurement Portal, E-Verify compliance, and drug-free workplace certification. Without additional opportunities under this code reflecting actual parecoxib procurement or clearer pharmaceutical purchasing patterns, the code shows minimal relevant recent activity and presents limited visibility into genuine demand signals for business development professionals pursuing state and local pharmaceutical contracts.